Caveolin and Caveolae in Age Associated Cardiovascular Disease

Overview

Journal J Geriatr Cardiol

Specialty Geriatrics

Date 2013 Apr 24

PMID 23610576

Citations 23

Authors

Heidi N Fridolfsson

Hemal H Patel

Affiliations

Soon will be listed here.

Abstract

It is estimated that the elderly (> 65 years of age) will increase from 13%-14% to 25% by 2035. If this trend continues, > 50% of the United States population and more than two billion people worldwide will be "aged" in the next 50 years. Aged individuals face formidable challenges to their health, as aging is associated with a myriad of diseases. Cardiovascular disease is the leading cause of morbidity and mortality in the United States with > 50% of mortality attributed to coronary artery disease and > 80% of these deaths occurring in those age 65 and older. Therefore, age is an important predictor of cardiovascular disease. The efficiency of youth is built upon cellular signaling scaffolds that provide tight and coordinated signaling. Lipid rafts are one such scaffold of which caveolae are a subset. In this review, we consider the importance of caveolae in common cardiovascular diseases of the aged and as potential therapeutic targets. We specifically address the role of caveolin in heart failure, myocardial ischemia, and pulmonary hypertension.

Citing Articles

Caveolin-3 and Caveolae regulate ventricular repolarization.

Markandeya Y, Gregorich Z, Feng L, Ramchandran V, O Hara T, Vaidyanathan R J Mol Cell Cardiol. 2023; 177:38-49.

PMID: 36842733 PMC: 10065933. DOI: 10.1016/j.yjmcc.2023.02.005.

Aging Alters the Formation and Functionality of Signaling Microdomains Between L-type Calcium Channels and β2-Adrenergic Receptors in Cardiac Pacemaker Cells.

Choi S, Vivas O, Baudot M, Moreno C Front Physiol. 2022; 13:805909.

PMID: 35514336 PMC: 9065441. DOI: 10.3389/fphys.2022.805909.

aPC/PAR1 confers endothelial anti-apoptotic activity via a discrete, β-arrestin-2-mediated SphK1-S1PR1-Akt signaling axis.

Molinar-Inglis O, Birch C, Nicholas D, Orduna-Castillo L, Cisneros-Aguirre M, Patwardhan A Proc Natl Acad Sci U S A. 2021; 118(49).

PMID: 34873055 PMC: 8670512. DOI: 10.1073/pnas.2106623118.

Electrophysiological and Molecular Mechanisms of Sinoatrial Node Mechanosensitivity.

Turner D, Kang C, Mesirca P, Hong J, Mangoni M, Glukhov A Front Cardiovasc Med. 2021; 8:662410.

PMID: 34434970 PMC: 8382116. DOI: 10.3389/fcvm.2021.662410.

Role of neuronal nitric oxide synthase on cardiovascular functions in physiological and pathophysiological states.

Ally A, Powell I, Ally M, Chaitoff K, Nauli S Nitric Oxide. 2020; 102:52-73.

PMID: 32590118 PMC: 7375925. DOI: 10.1016/j.niox.2020.06.004.

References

Woodman S, Park D, Cohen A, Cheung M, Chandra M, Shirani J . Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem. 2002; 277(41):38988-97. DOI: 10.1074/jbc.M205511200. View

McMurray J, Pfeffer M . Heart failure. Lancet. 2005; 365(9474):1877-89. DOI: 10.1016/S0140-6736(05)66621-4. View

Ju H, Zou R, Venema V, Venema R . Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem. 1997; 272(30):18522-5. DOI: 10.1074/jbc.272.30.18522. View

Kawabe J, Okumura S, Lee M, Sadoshima J, Ishikawa Y . Translocation of caveolin regulates stretch-induced ERK activity in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004; 286(5):H1845-52. DOI: 10.1152/ajpheart.00593.2003. View

Razani B, Combs T, Wang X, Frank P, Park D, Russell R . Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem. 2001; 277(10):8635-47. DOI: 10.1074/jbc.M110970200. View

Murry C, Jennings R, Reimer K . Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74(5):1124-36. DOI: 10.1161/01.cir.74.5.1124. View

OBrien J, Howlett S . Simulated ischemia-induced preconditioning of isolated ventricular myocytes from young adult and aged Fischer-344 rat hearts. Am J Physiol Heart Circ Physiol. 2008; 295(2):H768-77. DOI: 10.1152/ajpheart.00432.2008. View

Jahangir A, Sagar S, Terzic A . Aging and cardioprotection. J Appl Physiol (1985). 2007; 103(6):2120-8. DOI: 10.1152/japplphysiol.00647.2007. View

Zhao Y, Zhao Y, Mirza M, Huang J, Potula H, Vogel S . Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest. 2009; 119(7):2009-18. PMC: 2701851. DOI: 10.1172/JCI33338. View

10.

Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B . Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001; 293(5539):2449-52. DOI: 10.1126/science.1062688. View

11.

Zager R, Johnson A, Hanson S, dela Rosa V . Altered cholesterol localization and caveolin expression during the evolution of acute renal failure. Kidney Int. 2002; 61(5):1674-83. DOI: 10.1046/j.1523-1755.2002.00316.x. View

12.

Tsutsumi Y, Horikawa Y, Jennings M, Kidd M, Niesman I, Yokoyama U . Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation. 2008; 118(19):1979-88. PMC: 2676165. DOI: 10.1161/CIRCULATIONAHA.108.788331. View

13.

Wunderlich C, Schober K, Schmeisser A, Heerwagen C, Tausche A, Steinbronn N . The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium. J Mol Cell Cardiol. 2008; 44(5):938-47. DOI: 10.1016/j.yjmcc.2008.02.275. View

14.

Balijepalli R, Kamp T . Caveolae, ion channels and cardiac arrhythmias. Prog Biophys Mol Biol. 2009; 98(2-3):149-60. PMC: 2836876. DOI: 10.1016/j.pbiomolbio.2009.01.012. View

15.

Newman T, Severs N, Skepper J . The pathway of atrial natriuretic peptide release--from cell to plasma. Cardioscience. 1991; 2(4):263-72. View

16.

Patel H, Head B, Petersen H, Niesman I, Huang D, Gross G . Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and delta-opioid receptors. Am J Physiol Heart Circ Physiol. 2006; 291(1):H344-50. DOI: 10.1152/ajpheart.01100.2005. View

17.

Jasmin J, Mercier I, Dupuis J, Tanowitz H, Lisanti M . Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation. 2006; 114(9):912-20. DOI: 10.1161/CIRCULATIONAHA.106.634709. View

18.

Bucci M, Gratton J, Rudic R, Acevedo L, Roviezzo F, Cirino G . In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 2000; 6(12):1362-7. DOI: 10.1038/82176. View

19.

Ignarro L, Cirino G, Casini A, Napoli C . Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol. 1999; 34(6):879-86. DOI: 10.1097/00005344-199912000-00016. View

20.

Uray I, Connelly J, Frazier O, Taegtmeyer H, Davies P . Mechanical unloading increases caveolin expression in the failing human heart. Cardiovasc Res. 2003; 59(1):57-66. DOI: 10.1016/s0008-6363(03)00352-3. View